An award of up to $42 million from the Advanced Research Projects Agency for Health (ARPA-H) has been secured by a CMU-led team to accelerate the development of implantable, cell-based bioelectronic devices that deliver patient-specific therapy and monitor disease status, for conditions like hypo- and hyperthyroidism, in real time.

A Carnegie Mellon University-led team has secured an award of up to $42 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development of implantable, cell-based bioelectronic devices that deliver patient-specific therapy and monitor disease status, for conditions like hypo- and hyperthyroidism, in real time. This award is part of the ARPA-H REACT program, which supports the advancement of implantable bioelectronic devices to improve patient management of chronic diseases.

Burak Ozdoganlar, professor of mechanical engineering at Carnegie Mellon University, will head the Biointegrated Implantable Systems for Cell-based Sensing and Therapy (BIO-INSYNC) project as the primary investigator. This effort is part of the ongoing Bioelectric Medicine Initiative at Carnegie Mellon University… Continue reading.